– Reuters
Solid Biosciences Granted FDA Orphan Drug Designation For Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003; Patient Dosing Expected To Begin Mid-To-Late Q1 2024
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for
